Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom.

ABSTRACT:

Background

Cervical dystonia (CD) involves painful involuntary contraction of the neck and shoulder muscles and abnormal posture in middle-aged adults. Botulinum neurotoxin type A (BoNT-A) is effective in treating CD but little is known about its associated cost-effectiveness.

Objective

To evaluate the cost-effectiveness of abobotulinumtoxinA for treating CD from the UK payer perspective.

Methods

A Markov model was developed to evaluate the cost-effectiveness of abobotulinum-toxinA versus best supportive care (BSC) in CD, with a lifetime horizon and health states for response, nonresponse, secondary nonresponse, and BSC in patients with CD (mean age: 53 years; 37% male). Clinical improvement measured using Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) wa

SUBMITTER: Muthukumar M 

PROVIDER: S-EPMC5402907 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature